Cancer Board Gathers: Grants and Closed Doors Await
Published Date: 8/8/2025
Notice
Summary
The National Cancer Advisory Board is meeting on September 4, 2025, both in person and online to discuss cancer research updates and review grant applications. This meeting affects researchers and organizations seeking funding, with some parts closed to protect private info. If you want to join or comment, get ready to show ID and act fast—this is your chance to be part of the cancer-fighting conversation!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
NCI Will Review Grant Applications
On September 4, 2025, the National Cancer Advisory Board will review and evaluate grant applications during a closed session from 2:20 p.m. to 4:00 p.m. This meeting affects researchers and organizations seeking NCI funding because grant applications and related discussions will be considered on that date at the NCI–Shady Grove campus in Rockville, MD.
Public Access, ID, and Comment Rules
The meeting on September 4, 2025 is open to the public from 9:00 a.m. to 2:20 p.m. and may be viewed live via NIH Videocast (http://videocast.nih.gov/). Visitors to the NCI–Shady Grove campus must show one form of identification (for example, a government-issued photo ID, driver's license, or passport), and anyone needing special assistance to view the virtual meeting should notify the listed Contact Person in advance. Any interested person may file written comments with the committee by sending a statement (including name, address, phone number, and affiliation) to the Contact Person.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-15077, Self-Regulatory Organizations; Miami International Securities Exchange, LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Exchange Rule 307, Position Limits, and Exchange Rule 309, Exercise Limits To Allow the Exchange To Increase the Position and Exercise Limits for iShares Bitcoin Trust ETF
MIAX is boosting the maximum number of iShares Bitcoin Trust ETF options traders can hold and exercise, raising the limits from 25,000 contracts to a higher level. This change helps traders who want to handle bigger Bitcoin ETF option positions starting right away. If you trade these options, get ready for more room to grow your moves and potentially your profits!
Next: 2025-15079, Office of the Director, National Institutes of Health; Notice of Meeting
The National Institutes of Health (NIH) is holding a hybrid meeting for the Council of Councils on September 11-12, 2025. This meeting affects researchers and grant applicants, as it includes open sessions for program updates and a closed session to review grant applications confidentially. Anyone interested can join virtually or in person, with no direct money changes announced but important grant decisions happening behind the scenes.